Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Thomas Ottoboni"'
Autor:
Thomas Ottoboni, Eugene R. Viscusi, Richard A Pollak, Barry Quart, Joseph F. Dasta, Jayne Pawasauskas
Publikováno v:
Regional Anesthesia & Pain Medicine. 45:117-123
Background and objectives Obtaining consistent efficacy beyond 12–24 hours with local anesthetics, including extended-release formulations, has been a challenging goal. Inflammation resulting from surgery lowers the pH of affected tissues, reducing
Publikováno v:
Drug Design, Development and Therapy
Thomas Ottoboni, 1 Laura Lerner, 1 Arlene Santhouse 2 1Pharmaceutical and Translational Science, Heron Therapeutics, Inc, San Diego, CA, USA; 2Medical Affairs, Heron Therapeutics, Inc, San Diego, CA, USACorrespondence: Thomas OttoboniPharmaceutical a
Publikováno v:
Drug Design, Development and Therapy
Introduction Fosaprepitant, an intravenous (IV) aprepitant prodrug for chemotherapy-induced nausea and vomiting prophylaxis, is associated with systemic and infusion-site reactions attributed in part to its surfactant, polysorbate 80. HTX-019 is an I
Autor:
Thomas Ottoboni, Joseph F. Dasta, Eugene R. Viscusi, Jayne Pawasauskas, Barry Quart, Richard A Pollak
Publikováno v:
Regional Anesthesia and Pain Medicine
To the Editor We appreciate the comments provided by Hafer and Johnson[1][1] regarding our recent manuscript.[2][2] Their primary concern appears to be the clinical evidence supporting the analgesic properties of HTX-011 beyond 24 hours. HTX-011 is a
Autor:
Michael Lauw, Thomas Ottoboni, Kimberly Manhard, Barry D. Quart, Neil J. Clendeninn, Matt Cravets, Mary Rose Keller
Publikováno v:
Future oncology (London, England). 15(8)
Aim: HTX-019 (CINVANTI® [aprepitant injectable emulsion]) is a neurokinin 1 receptor antagonist approved for preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV). HTX-019 is free of polysorbate 80 and other synthetic surfacta
Publikováno v:
Future oncology (London, England). 15(3)
Aim: Fosaprepitant, an intravenous neurokinin-1 receptor antagonist for chemotherapy-induced nausea and vomiting, contains polysorbate 80, which is associated with infusion-site adverse events (ISAEs) and hypersensitivity systemic reactions (HSRs). T
Autor:
Eugene R. Viscusi, Guy Boccia, Thomas Ottoboni, Mary Rose Keller, Alice Chu, Barry Quart, Oscare DeLeon-Casasola, Tong J. Gan, Sanjay S. Patel, Erol Onel
Publikováno v:
Journal of the American College of Surgeons. 225:e37
Publikováno v:
Journal of Experimental Pharmacology
Thomas Ottoboni,1 Mark S Gelder,1 Erin O’Boyle2 1Heron Therapeutics, Inc., Redwood City, CA, USA; 2FibroGen, Inc., San Francisco, CA, USA Abstract: Granisetron and other 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are first-line agents